Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s):  CLAZF

Healthcare Biotechnology
Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.


TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc > Patience is a key element of success.... B.Gates
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(310)
•••
Comment by AngelaLon Apr 20, 2021 7:23pm
220 Views
Post# 33034165

RE:RE: Patience is a key element of success.... B.Gates

RE:RE: Patience is a key element of success.... B.GatesAs far as I understand from the PR's to date, everything is loaded and ready to go into a Phase 1 study. The beauty of their PAH program is that they can leapfrog from a quick Phase 1 study on healthies right to a small Phase 2 in folks with bad PAH. A Phase 2 pilot like that can be done in a few months. Assuming R-107 works in that Phar 2, then they have proof of principle and the stock is worth a fortune. Let's hope they announce something soon about when the Phase 1 starts. I am loading up on stock fast, before that news happens. 
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities